The intranasal vaccination strategy and IgA-based therapeutic antibodies for the influenza infection (66, 67) and intranasal administration of a MERS-derived vaccine (68) clearly exploit the beneficial role of IgA antibodies at epithelial layers. The gene discussed is CD79A; the disease is influenza.